Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
← catalyst calendarNCT07073014 · readout ≤ 5,248 d
Sponsored by BioMarin Pharmaceutical (industry) · BMRN — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
140estimated
Sites
23
Countries
Australia, Canada, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-20 | actual | When the study began enrolling |
| Primary completion | Dec 2040 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2040 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypochondroplasia
Intervention
- Drug: Vosoritide
Primary outcome
what the primary-completion date above is the date OFEvaluate the long-term efficacy of vosoritide treatment until final adult height (FAH)
measured Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males
Permalink · BMRN's whole pipeline · Catalyst calendar · Every registered study · What changed